Long term survival of patients with recurrent or refractory germ cell tumors after high dose chemotherapy

Cancer

Volumn 79, Issue 1, 1997, Pages 161-168

  Beyer, Jörg ^a   Kingreen, Dorothea ^a   Krause, Manuela ^a   Schleicher, Jan ^a   Schwaner, Ingo ^a   Schwella, Nimrod ^a   Huhn, Dieter ^a   Siegert, Wolfgang ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

antineoplastic agents toxicity; antineoplastic agents therapeutic use; bone marrow transplantation; hematopoietic stem cell transplantation; prognosis; salvage therapy; survival analysis; testicular neoplasms; treatment outcome

Indexed keywords

CARBOPLATIN; ETOPOSIDE; IFOSFAMIDE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG MEGADOSE; FEMALE; GERM CELL TUMOR; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; OTOTOXICITY; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; GERMINOMA; HUMANS; IFOSFAMIDE; MALE; MEDIASTINAL NEOPLASMS; MIDDLE AGED; RETROPERITONEAL NEOPLASMS; SALVAGE THERAPY; SURVIVORS; TESTICULAR NEOPLASMS;

EID: 0031014942     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970101)79:1<161::AID-CNCR23>3.0.CO;2-1     Document Type: Article

References (30)

1. Loehrer PJ, Lauer R, Roth BJ, Williams SD, Kalasinski LA, Einhorn LH. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med 1988;109:540-6.
2. Motzer RJ, Geller NL, Tan CCY, Herr H, Morse M, Fair W, et al. Salvage chemotherapy for patients with germ cell tumors. Cancer 1991;67:1305-10.
3. Nichols CR, Roth BJ, Loehrer PJ, Williams SD, Einhorn LH. Salvage chemotherapy for recurrent germ cell cancer. Semin Oncol 1994;21(Suppl 12):102-8.
4. Beyer J, Bokemeyer C, Schmoll HJ, Siegert W. Treatment intensification in disseminated germ-cell tumors. World J Urol 1994;12:207-13.
5. Motzer RJ, Bosl GJ. High-dose chemotherapy for resistant germ cell tumors: recent advances and future directions. J Natl Cancer Inst 1992;84:1703-9.
6. Siegert W, Beyer J, Strohscheer I, Baurmann H, Oettle H, Zingsem J, et al. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group. J Clin Oncol 1994;12:1223-31.
7. Harstrick A, Schmoll HJ, Wilke H, Köhne-Wömpner CH, Stahl M, Schöber C, et al. Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma. J Clin Oncol 1991;9:1549-55.
8. Murphy BR, Breeden ES, Donohue JP, Messemer J, Walsh W, Roth BJ, et al. Surgical salvage of chemorefractory germ cell tumors. J Clin Oncol 1993;11:324-9.
9. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
10. Cooper M, Einhorn LH. Maintenance chemotherapy with daily oral etoposide following salvage therapy in patients with germ cell tumors. J Clin Oncol 1995;13:1167-9.
11. Horwich A, A'Hearn R, Gildersleve J, Dearnaley D. Prognostic factor analysis of conventional dose salvage therapy of patients with metastatic non seminomatous germ cell cancer [abstract 715]. Proc Am Soc Clin Oncol 1993;12:232.
12. Droz JP, Kramar A, Nichols CR, Schmoll HJ, Auperin A, Harstrick A, et al. Second line chemotherapy with ifosfamide, cisplatin and either etoposide or vinblastine in recurrent germ cell cancer: assignment of prognostic groups [abstract 704]. Proc Am Soc Clin Oncol 1993;12:229.
13. Saxman SB, Nichols CR, Einhorn LH. Salvage chemotherapy in patients with extragonadal nonseminomatous germ cell tumors: the Indiana University experience. J Clin Oncol 1994;12:1390-3.
14. Nichols CR, Andersen J, Lazarus HM, Fisher H, Greer J, Stadtmauer EA, et al. High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group protocol. J Clin Oncol 1992;10:558-63.
15. Motzer RJ, Gulati SC, Crown JP, Weisen S, Doherty M, Herr H, et al. High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Cancer 1991;69:550-6.
16. Broun ER, Nichols CR, Turns M, Williams SD, Loehrer PJ, Roth BJ, et al. Early salvage therapy for germ cell cancer using high dose chemotherapy with autologous bone marrow support. Cancer 1994;73:1716-20.
17. Lotz JP, Andre T, Donsimoni R, Firmin C, Bouleuc C, Bonnak H, et al. High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults. Cancer 1995;75:874-85.
18. Broun ER, Nichols CR, Mandanas R, Salzman D, Turns M, Hromas R, et al. Dose escalation study of high-dose carboplatin and etoposide with autologous bone marrow support in patients with recurrent and refractory germ cell tumors. Bone Marrow Transplant 1995;16:353-8.
19. Linkesch W, Greinix HT, Höcker P, Krainer M, Wagner A. Longterm follow up of phase I/II trial of ultrahigh carboplatin, VP16, cyclophosphamide with ABMT in refractory or relapsed NSGCT [abstract 717]. Proc Am Soc Clin Oncol 1993;12:232.
20. Broun ER, Nichols CR, Einhorn LH, Tricot GJK. Salvage therapy with high-dose chemotherapy and autologous bone marrow support in the treatment of primary nonseminomatous mediastinal germ cell tumors. Cancer 1991;68:1513-5.
21. Droz JP, Pico JL, Ghosn M, Gouyette A, Baume D, Piot G, et al. Long-term survivors after salvage high-dose chemotherapy with bone marrow rescue in refractory germ cell cancer. Eur Cancer 1991;27:831-5.
22. Broun ER, Nichols CR, Kneebone P, Williams SD, Loehrer PA, Einhorn LH, et al. Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann Intern Med 1992;117:124-8.
23. Droz JP, Kramar A, Pico JL. Prediction of long-term response after high-dose chemotherapy with autologous bone marrow transplantation in the salvage treatment of non-seminomatous germ cell tumors. Eur J Cancer 1993;29A:818-21.
24. Motzer RJ, Mazumdar M, Bosl GJ, Bajorin DF, Amsterdam A, Vlamis V. High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity. J Clin Oncol 1996;14:1098-105.
25. Beyer J, Kramar A, Mandanas R, Linkesch W, Greinix A, Droz JP, et al. High-dose chemotherapy (HDCT) as salvage treatment in germ cell tumors (GCT): a multivariate analysis of prognostic variables [abstract 593]. Proc Am Soc Clin Oncol 1996;15:239.
26. Nichols CR, Tricot G, Williams SD, van Besien K, Loehrer PJ, Roth BJ, et al. Dose-intensive chemotherapy in refractory germ cell cancer - a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 1989;7:932-9.
27. Osanto S, Bukman A, van Hoek F, Sterk PJ, de Laat JAPM, Hermans J. Long-term effects of chemotherapy in patients with testicular cancer. J Clin Oncol 1992;10:574-9.
28. Bokemeyer C, Schmoll HJ. Treatment of testicular cancer and the development of secondary malignancies. J Clin Oncol 1995;13:283-92.
29. Bokemeyer C, Schmoll HJ, Kuczyk MA, Beyer J, Siegert W. Risk of secondary leukemia following high cumulative doses of etoposide during chemotherapy for testicular cancer. J Natl Cancer Inst 1995;87:58-60.
30. Domenech J, Linassier C, Gihana E, Dayan A, Truglio D, Bout M, et al. Prolonged impairment of hematopoiesis after high-dose therapy followed by autologous bone marrow transplantation. Blood 1995;85:3320-7.